Clinical Trial Update: Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial exploring anlotinib plus PD-1 antibody for second-line and above treatment of advanced solid tumors in Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Anlotinib (anlotinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Advanced Solid Tumor | Phase 2, Phase 3 | Status: UNKNOWN